These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 16734513)

  • 21. Current and future therapy in Alzheimer's disease.
    van Marum RJ
    Fundam Clin Pharmacol; 2008 Jun; 22(3):265-74. PubMed ID: 18485144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody-mediated immunotherapy for Alzheimer's disease.
    Solomon B
    Curr Opin Investig Drugs; 2007 Jul; 8(7):519-24. PubMed ID: 17659471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Active immunization against Alzheimer's beta-amyloid peptide using phage display technology.
    Solomon B
    Vaccine; 2007 Apr; 25(16):3053-6. PubMed ID: 17287054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hopes remain for an Alzheimer's vaccine.
    Schenk D
    Nature; 2004 Sep; 431(7007):398. PubMed ID: 15385984
    [No Abstract]   [Full Text] [Related]  

  • 25. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapy against APP beta-secretase cleavage site improves cognitive function and reduces neuroinflammation in Tg2576 mice without a significant effect on brain abeta levels.
    Rakover I; Arbel M; Solomon B
    Neurodegener Dis; 2007; 4(5):392-402. PubMed ID: 17536186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amyloid beta peptides with an additional cysteine residue can enhance immunogenicity and reduce the amyloid beta burden in an Alzheimer's disease mouse model.
    Matsuda J; Kaminaka K; Nozaki C
    Biochem Biophys Res Commun; 2009 Apr; 382(1):149-52. PubMed ID: 19265678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Disease modifying therapy for AD?
    Golde TE
    J Neurochem; 2006 Nov; 99(3):689-707. PubMed ID: 17076654
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's disease.
    Schenk DB; Seubert P; Grundman M; Black R
    Neurodegener Dis; 2005; 2(5):255-60. PubMed ID: 16909006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Autoantibodies against beta-amyloid are common in Alzheimer's disease and help control plaque burden.
    Kellner A; Matschke J; Bernreuther C; Moch H; Ferrer I; Glatzel M
    Ann Neurol; 2009 Jan; 65(1):24-31. PubMed ID: 19194878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain.
    Boche D; Zotova E; Weller RO; Love S; Neal JW; Pickering RM; Wilkinson D; Holmes C; Nicoll JA
    Brain; 2008 Dec; 131(Pt 12):3299-310. PubMed ID: 18953056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The underestimated potential of the immune system in prevention of Alzheimer's disease pathology.
    Mohajeri MH
    Bioessays; 2007 Sep; 29(9):927-32. PubMed ID: 17688240
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alzheimer's disease: Moving towards a vaccine.
    Holtzman DM
    Nature; 2008 Jul; 454(7203):418-20. PubMed ID: 18650906
    [No Abstract]   [Full Text] [Related]  

  • 34. [Alzheimer's disease: therapeutic perspectives].
    Dubois B; De Souza L; Allali G; Kalafat M; Sarazin M
    Bull Acad Natl Med; 2008 Feb; 192(2):333-42; discussion 343-4. PubMed ID: 18819687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease.
    Pákáski M; Kálmán J
    Neurochem Int; 2008 Nov; 53(5):103-11. PubMed ID: 18602955
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Alzheimer's disease: from brain lesions to new drugs].
    Forette F; Hauw JJ
    Bull Acad Natl Med; 2008 Feb; 192(2):363-78; discussion 378-80. PubMed ID: 18819689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-amyloid-beta immunotherapy in Alzheimer's disease: ACC-001 clinical trials are ongoing.
    Ryan JM; Grundman M
    J Alzheimers Dis; 2009; 17(2):243. PubMed ID: 19502708
    [No Abstract]   [Full Text] [Related]  

  • 38. Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers.
    Robert R; Dolezal O; Waddington L; Hattarki MK; Cappai R; Masters CL; Hudson PJ; Wark KL
    Protein Eng Des Sel; 2009 Mar; 22(3):199-208. PubMed ID: 18927231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inflammation and therapeutic vaccination in CNS diseases.
    Weiner HL; Selkoe DJ
    Nature; 2002 Dec 19-26; 420(6917):879-84. PubMed ID: 12490962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and therapeutic efficacy of phage-displayed beta-amyloid epitopes.
    Esposito M; Luccarini I; Cicatiello V; De Falco D; Fiorentini A; Barba P; Casamenti F; Prisco A
    Mol Immunol; 2008 Feb; 45(4):1056-62. PubMed ID: 17850871
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.